Immunogenic compositions of
View Patent ↗The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus . The present invention also relates to immunogenic compositions, comprising Staphylococcus aureus capsule polysaccharides conjugated to a carrier protein. In addition, the invention relates to methods of inducing an immune response in subjects against Staphylococcus aureus using immunogenic compositions of the Staphylococcus aureus polypeptides and capsule polysaccharides.
1. An immunogenic composition comprising an isolated Staphylococcus aureus manganese transporter protein C (MntC protein), an isolated Staphylococcus aureus capsular polysaccharide type 5 conjugated to CRM 197 , and an isolated S. aureus capsular polysaccharide type 8 conjugated to CRM 197 , wherein the capsular polysaccharide type 5 has a molecular weight of between 20 and 1000 kDa and the capsular polysaccharide type 8 has a molecular weight of between 20 and 1000 kDa.
2. The immunogenic composition of claim 1 , wherein the MntC is produced recombinantly.
3. The immunogenic composition of claim 1 , wherein the capsular polysaccharide type 5 has a molecular weight of between 70 and 800 kDa, between 70 and 300 kDa, or between 70 and 150 kDa.
4. The immunogenic composition of claim 1 , wherein the capsular polysaccharide type 5 is between 10% and 100% O-acetylated, between 50% and 100% O-acetylated, or between 75% and 100% O-acetylated.
5. The immunogenic composition of claim 1 , wherein the capsular polysaccharide type 8 has a molecular weight of between 70 and 800 kDa, between 70 and 300 kDa, or between 70 and 150 kDa.
6. The immunogenic composition of claim 1 , wherein the capsular polysaccharide type 8 is between 10% and 100% O-acetylated, between 50% and 100% O-acetylated, or between 75% and 100% O-acetylated.
7. The immunogenic composition of claim 1 , wherein the S. aureus MntC protein is a lipidated or a non-lipidated protein.
8. The immunogenic composition of claim 1 , further comprising an adjuvant.
9. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
10. The immunogenic composition of claim 1 , further comprising an antigen selected from the group consisting of Opp3a, DltD, HtsA, LtaS, IsdA, IsdB IsdC, SdrC, SdrD, SdrE, SdrF, SdrG, SdrH, SrtA, SpA, Sbi, FmtB, alpha-hemolysin (hla), beta-hemolysin, fibronectin-binding protein A (fnbA), fibronectin-binding protein B (fnbB), coagulase, Fig, map, Panton-Valentine leukocidin (pvl), alpha-toxin and its variants, gamma toxin (hlg) and variants, ica, immunodominant ABC transporter, Mg2+ transporter, Ni ABC transporter, RAP, autolysin, laminin receptors, IsaA/PisA, IsaB/PisB, SPOIIIE, SsaA, EbpS, Sas A, SasF, SasH, EFB (FIB), SBI, Npase, EBP, bone sialo binding protein II, aureolysin precursor (AUR)/Sepp1, CNA, and fragments thereof such as M55, TSST-1, mecA, poly-N-acetylglucosamine (PNAG/dPNAG) exopolysaccharide, GehD, EbhA, EbhB, SSP-1, SSP-2, HBP, vitronectin binding protein, HarA, EsxA, EsxB, Enterotoxin A, Enterotoxin B, Enterotoxin C1, and novel autolysin.
11. A method of inducing an immune response against Staphylococcus aureus comprising administering to a subject an immunologically effective amount of the immunogenic composition of claim 1 .
12. The method of claim 11 , wherein the immune response reduces a disease associated with a staphylococcal organism in a subject.
13. The method of claim 12 , wherein the disease is selected from the group consisting of invasive S. aureus disease, sepsis, and carriage.
14. The method of claim 11 , wherein the immune response induced comprises the generation of antibodies having opsonophagocytic activity (OPA) against S. aureus.